ABSTRACT
The 2017 American College of Cardiology and American Heart Association Task Force on Clinical Practice Guidelines on the treatment of hypertension recommended lifestyle modification and monitoring every 3 to 6 months for patients with stage 1 hypertension. However, the guidelines did not include recommendations for patients whose blood pressure is unresponsive to lifestyle therapy. The authors review the updated AHA position statement, which is meant to help clinicians manage patients with stage 1 hypertension and a low 10-year risk of atherosclerotic cardiovascular disease.
- Copyright © 2022 The Cleveland Clinic Foundation. All Rights Reserved.
- Abel Hooker, MD⇑
- Department of Internal Medicine, Hennepin County Medical Center: Hennepin Healthcare, Minneapolis, MN
- Address:
Abel Hooker, MD, Department of Internal Medicine, Hennepin County Medical Center: Hennepin Healthcare, 730 S 8th Street, Minneapolis, MN 55415; Abel.HookerMendez{at}hcmed.org
- Kevin G. Buda, DO
- Maarya Pasha, MD
ABSTRACT
The 2017 American College of Cardiology and American Heart Association Task Force on Clinical Practice Guidelines on the treatment of hypertension recommended lifestyle modification and monitoring every 3 to 6 months for patients with stage 1 hypertension. However, the guidelines did not include recommendations for patients whose blood pressure is unresponsive to lifestyle therapy. The authors review the updated AHA position statement, which is meant to help clinicians manage patients with stage 1 hypertension and a low 10-year risk of atherosclerotic cardiovascular disease.
- Copyright © 2022 The Cleveland Clinic Foundation. All Rights Reserved.
In this issue
Jump to section
- Article
- ABSTRACT
- CLINICAL SETTING
- INTENDED AUDIENCE
- WHO WROTE THE GUIDELINES?
- WHAT ARE THE MAIN RECOMMENDATIONS?
- SIGNIFICANCE OF LIFETIME RISK FOR CVD AND PROGRESSION OF HYPERTENSION
- BLUNTING THE PROGRESSION OF HYPERTENSION WITH LIFESTYLE THERAPY
- RECOMMENDATIONS WHEN LIFESTYLE THERAPY FAILS
- WHAT IS DIFFERENT FROM PRIOR GUIDELINES?
- DO OTHER SOCIETIES AGREE?
- HOW WILL THIS CHANGE DAILY PRACTICE?
- WHEN WOULD THE GUIDELINES NOT APPLY?
- THE BOTTOM LINE
- DISCLOSURES
- REFERENCES
- Info & Metrics